These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
215 related items for PubMed ID: 36688904
1. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review. Wang Z, Wu R, Li C, Cheng K, Di Y, Lv T, Liu H, Song Y. Anticancer Drugs; 2023 Nov 01; 34(10):1069-1075. PubMed ID: 36688904 [Abstract] [Full Text] [Related]
2. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report. Wang Z, Shi Y, Zhang P, Chen Y. Chin Clin Oncol; 2023 Dec 01; 12(6):70. PubMed ID: 38195077 [Abstract] [Full Text] [Related]
9. Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review. Gu R, Shi Z, Duan T, Song M. Onco Targets Ther; 2021 Oct 07; 14():5107-5113. PubMed ID: 34707369 [Abstract] [Full Text] [Related]
11. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report. Ning S, Shi C, Zhang H, Li J. Medicine (Baltimore); 2021 Dec 23; 100(51):e27999. PubMed ID: 34941039 [Abstract] [Full Text] [Related]
15. Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report. Li J, Liu J, Zhang G, Hu W, Wang X, Liu J. Am J Case Rep; 2023 Nov 07; 24():e942150. PubMed ID: 37934724 [Abstract] [Full Text] [Related]
17. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial. Leonetti A, Minari R, Boni L, Gnetti L, Verzè M, Ventura L, Musini L, Tognetto M, Tiseo M. Clin Lung Cancer; 2021 Sep 07; 22(5):473-477. PubMed ID: 33762169 [Abstract] [Full Text] [Related]
18. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib. Yamamoto Y, Okamoto I, Otsubo K, Iwama E, Hamada N, Harada T, Takayama K, Nakanishi Y. Invest New Drugs; 2015 Oct 07; 33(5):1148-50. PubMed ID: 26334220 [Abstract] [Full Text] [Related]
19. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma. Liu Z, Wu Q, Li W, Li P, Huang L, Wang T, Zhou Q. Lung Cancer; 2023 Dec 07; 186():107386. PubMed ID: 37922771 [Abstract] [Full Text] [Related]
20. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report. Li Z, Li P, Yan B, Gao Q, Jiang X, Zhan Z, Yan Q, Lizaso A, Huang C. Thorac Cancer; 2020 Jan 07; 11(1):176-180. PubMed ID: 31766077 [Abstract] [Full Text] [Related] Page: [Next] [New Search]